Results 191 to 200 of about 37,820 (304)

Former smokers with severe eosinophilic asthma respond to benralizumab as effectively as never-smokers: a <i>post hoc</i> analysis of the ANANKE study. [PDF]

ERJ Open Res
Senna G, Brussino L, Aliani M, Altieri E, Bracciale P, Caiaffa MF, Cameli P, Canonica GW, Caruso C, Centanni S, De Michele F, Del Giacco S, Di Marco F, Malerba L, Menzella F, Pelaia G, Rogliani P, Romagnoli M, Schino P, Schroeder JW, Vultaggio A, D'Amato M, Caminati M.   +22 more
europepmc   +1 more source

Early and Sustained Asthma Control and Remission in Real-World Patients With Severe Eosinophilic Asthma Treated With Benralizumab: XALOC-2. [PDF]

Clin Exp Allergy
Penz E, Rothe T, Dupont L, Tran TN, Menzies-Gow A, Shavit A, Cohen D, Plate T, Kayaniyil S, Herreman A, Schuoler C, Emmanuel B, Lommatzsch M.   +12 more
europepmc   +1 more source

Resolving Endoplasmic Reticulum‐Protein Misfolding Restores Corticosteroid Sensitivity in Experimental Models of Severe Asthma

Allergy, EarlyView.
This study investigates the role of ER stress in steroid resistance in severe asthma. Results from advanced 3D models of human bronchial epithelial cells, steroid‐resistant severe asthma mouse models, and human severe asthma sputum samples show that treatment with ICS in combination with the ER stress inhibitor 4‐PBA significantly enhances steroid ...
Prabuddha S. Pathinayake, Alexandra C. Brown, Nikhil T. Awatade, Philip M. Hansbro, Katherine J. Baines, Richard Y. Kim, Nathan W. Bartlett, Jay C. Horvat, Peter A. B. Wark   +8 more
wiley   +1 more source

Real-World Effectiveness of Benralizumab in Severe Eosinophilic Asthma: A 32-Week Evaluation.

Int Arch Allergy Immunol
Özden Ş, Tepetam FM, Bozkurt Y, Terzioğlu Şahin F, Aynacı A, Avcı HF, Dursun M, Demirkol MA, Yıldırım N.   +8 more
europepmc   +1 more source

Analysis of Selected Serum Cytokines to Evaluate the Early Efficacy of Benralizumab, Dupilumab, and Mepolizumab in Severe Eosinophilic Asthma Treatment. [PDF]

Int J Mol Sci
Niemiec-Górska A, Labus Ł, Mielcarska S, Glück J, Czuba Z, Cyrnek M, Branicka O, Rymarczyk B, Gawlik R.   +8 more
europepmc   +1 more source

Anxiety, Depression, Schizophrenia, and Bipolar Disorder in Eosinophilic Esophagitis Patients: A Global Federated Cohort Analysis of Bidirectional Risks

Allergy, EarlyView.
Hui‐Chin Chang, Meng‐Che Wu, Torsten Zuberbier, Shuo‐Yan Gau   +3 more
wiley   +1 more source

Cytokine and Metabolomic Signatures of Mepolizumab Response Across Upper and Lower Airway Compartments in Severe Eosinophilic Asthma: An Exploratory Analysis. [PDF]

Pharmaceuticals (Basel)
Maniscalco M, Ambrosino P, Candia C, Di Stefano A, Gnemmi I, Zappa M, Ambrosino N, Visca D, Motta A.   +8 more
europepmc   +1 more source

Prevalence of Type 2 Inflammation in Chronic Obstructive Pulmonary Disease Patients With Frequent Exacerbations

Allergy, EarlyView.
Mireille C. Melles, Johannes C. C. M. in 't Veen, Dirk‐Jan Slebos, Frits M. E. Franssen, Marlies van Dijk, Pieter‐Paul W. Hekking   +5 more
wiley   +1 more source

MAIT Cells Suppress IgE‐Mediated Asthma via IFNγ‐Dependent B Cell Regulation

Allergy, EarlyView.
In this study, we demonstrate that MAIT cell antagonism during sensitization and challenge with HDM worsens the development of airway hyperreactivity without effects on type 2 or 17 associated cytokine production or lung inflammation. Rather, MAIT cells appear to regulate HDM‐induced asthma through direct inhibition of IgE production.
Angela M. Cannata, Jaclyn W. McAlees, Julie M. Hargis, Archana Shankar, Shouxiong Huang, Senad Divanovic, Ian P. Lewkowich   +6 more
wiley   +1 more source

Population Pharmacokinetics and Exposure-Response Analysis of Benralizumab in Chinese Adults, Adolescents, and Pediatric Participants with Severe Eosinophilic Asthma. [PDF]

Clin Pharmacokinet
Jin Y, Guiastrennec B, Stuke M, Yao Y, Zhang Y, Barker P, Jison M, Penland RC, Ding J, Lukka PB.   +9 more
europepmc   +1 more source